GlobeNewswire Inc.··NaMesoblast Hits Recruitment Milestone in Pivotal Back Pain Trial
Mesoblast completes recruitment of 300+ patients in pivotal Phase 3 trial for chronic back pain therapy, targeting mid-2027 results and Q3 2027 FDA filing.
MESOPhase 3 clinical trialFDA approval